Huiqing Zhang | Cancer | Best Researcher Award

Posted on by Pencis

Mr. Huiqing Zhang | Cancer | Best Researcher Award

Jiangxi Cancer Hospital | China

Author Profile

Scopus

📌 HUIQING ZHANG – A LEADING FIGURE IN DIGESTIVE ONCOLOGY

🏛 EARLY ACADEMIC PURSUITS

Huiqing Zhang embarked on his medical journey with a strong foundation in oncology, specializing in digestive oncology. His rigorous academic training provided him with extensive knowledge of gastrointestinal malignancies, diagnostic methodologies, and therapeutic advancements. His pursuit of excellence led him to gain specialized expertise in oncology, which would later define his career trajectory.

💼 PROFESSIONAL ENDEAVORS

Dr. Zhang has held key positions in prominent cancer institutions in China, demonstrating a steady and impactful career progression:

  • December 2018 – Present: Chief Physician, Department of Digestive Oncology, Jiangxi Cancer Hospital.
  • December 2015 – December 2018: Deputy Chief Physician, Department of Digestive Oncology, Jiangxi Cancer Hospital.
  • March 2017 – March 2018: Vice President (on secondment) and Deputy Chief Physician at Ganzhou Cancer Hospital.
  • December 2015 – November 2016: Visiting Scientist at MD Anderson Cancer Center, Gastroenterology.
  • November 2010 – December 2015: Attending Physician, Department of Digestive Oncology, Jiangxi Cancer Hospital.
  • August 2008 – November 2010: Physician, Oncology Department, Jiangxi Cancer Hospital.

Throughout his career, Dr. Zhang has played a pivotal role in advancing digestive oncology treatments, contributing significantly to the hospital’s clinical and research excellence.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER

Dr. Zhang’s research primarily focuses on gastrointestinal cancer therapies, tumor microenvironments, and precision medicine approaches. His work has contributed to the development of innovative treatment modalities, improving patient outcomes in digestive oncology. His tenure at MD Anderson Cancer Center exposed him to cutting-edge research methodologies, which he has integrated into his clinical practice in China.

🌍 IMPACT AND INFLUENCE

As a Chief Physician, Dr. Zhang has been instrumental in pioneering advanced treatment strategies for digestive cancer patients. His leadership at Jiangxi Cancer Hospital has strengthened its reputation as a leading institution for cancer care in China. Additionally, his role as Vice President at Ganzhou Cancer Hospital further expanded his influence in shaping policies and implementing progressive medical protocols.

📚 ACADEMIC CITATIONS

Dr. Zhang’s research contributions have been widely cited in scientific journals, reflecting his influence in the field of digestive oncology. His studies on novel therapeutic strategies and advancements in endoscopic cancer treatments are frequently referenced by oncologists and researchers worldwide.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zhang’s legacy is defined by his unwavering commitment to oncology research and patient care. His future contributions are expected to focus on expanding precision medicine applications, enhancing immunotherapy approaches, and fostering international collaborations to improve gastrointestinal cancer treatment. As a seasoned researcher and physician, he continues to inspire upcoming oncologists and remains a key figure in advancing cancer therapy in China and beyond.

📑NOTABLE PUBLICATIONS 

"Mutation on JmjC domain of UTX impaired its antitumor effects in pancreatic cancer via inhibiting G0S2 expression and activating the Toll-like signaling pathway" 

  • Authors: X., Shen, Xiaohua , S., Xiong, Shuping , S., Wang, Shengpeng , Y., Wan, Yiye , H., Zhang, Huiqing
  • Journal: Molecular Medicine
  • Year: 2024

Leilei Wu | Lung Cancer | Best Researcher Award

Posted on by Pencis

Dr. Leilei Wu | Lung Cancer | Best Researcher Award

Zhejiang Cancer Hospital | China

Author Profile

Scopus

Orcid ID

📘 BIOGRAPHY OF DR. LEILEI WU

🎓 EARLY ACADEMIC PURSUITS

Dr. Leilei Wu laid the groundwork for his exceptional career by pursuing an M.D. and Ph.D., focusing his academic efforts on advancing knowledge in thoracic surgery. During his formative years, he displayed a strong dedication to understanding the complexities of lung cancer and esophageal cancer, particularly their diagnosis and treatment.

🏥 PROFESSIONAL ENDEAVORS

As a member of the Department of Thoracic Surgery at Zhejiang Cancer Hospital, Hangzhou, Dr. Wu has combined surgical expertise with groundbreaking research. He is actively involved in clinical and translational studies, making substantial contributions to advancing thoracic surgery techniques and treatment protocols for lung and esophageal cancer.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER

Dr. Wu's research focuses on innovative treatment strategies for thoracic malignancies. His contributions include:

  1. Exploring the synergy of AMG-510 with cisplatin for increased antitumor effects in KRAS G12C mutant lung adenocarcinoma.
  2. Studying the prognosis and risks of diabetes mellitus post-lung transplantation, offering critical insights into patient care.
  3. Investigating the compound Osalmid for its dual effects in inhibiting lung adenocarcinoma progression and enhancing EGFR-TKI therapy sensitivity.

🌍 IMPACT AND INFLUENCE

Dr. Wu's research has gained international recognition through prestigious conferences:

  • Poster Presentation: 31st European Conference on General Thoracic Surgery, Milano, Italy (2023)
    • “AMG-510 and Cisplatin Combination Increases Antitumor Effect in Lung Adenocarcinoma with KRAS G12C Mutation.”
  • Oral Presentation: 31st European Conference on General Thoracic Surgery, Milano, Italy (2023)
    • “Prognosis and Risk of Diabetes Mellitus in Patients After Lung Transplantation.”
  • Poster Presentation: IASLC World Conference on Lung Cancer, San Diego, USA (2024)
    • “Osalmid Inhibits Lung Adenocarcinoma Progression and Sensitizes to EGFR-TKIs: A Preclinical Study.”

📈 ACADEMIC CITES AND RECOGNITION

Dr. Wu's innovative work has garnered significant attention from peers, highlighting his commitment to excellence. His contributions to thoracic oncology are cited frequently, reflecting the relevance and influence of his research in the scientific community.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Wu aims to further transform thoracic oncology by:

  • Developing precision medicine techniques tailored to individual genetic profiles.
  • Refining minimally invasive surgical methods.
  • Mentoring the next generation of thoracic surgeons and researchers.

His dedication to bridging the gap between clinical practice and scientific discovery ensures a lasting impact on thoracic surgery and oncology worldwide.

🔑 KEYWORDS

Thoracic Surgery, Lung Cancer, Esophageal Cancer, Translational Research, AMG-510, Cisplatin, KRAS G12C Mutation, Osalmid, EGFR-TKI Sensitivity, Zhejiang Cancer Hospital, Thoracic Oncology Innovation.

📑NOTABLE PUBLICATIONS 

"The association between the cough and the inflation of esophagus" 

  • Authors: Wu, L.-L. , Xie, D.
  • Journal: Respiratory Investigation
  • Year: 2024

"Apoptosis and cuproptosis Co-activated Copper-based metal-organic frameworks for cancer therapy" 

  • Authors: Li, K. , Wu, L. , Wang, H. , Wang, J. , Xie, D.
  • Journal: Journal of Nanobiotechnology
  • Year: 2024

"The molecular characteristics could supplement the staging system of pT2/T3N0M0 esophageal squamous cell carcinoma: a translational study based on a cohort with over 20 years of follow-up" 

  • Authors: Jiang, W.-M. , Tian, J.-Y. , Guo, Y.-H. , Wu, L.-L. , Ma, G.-W.
  • Journal: Cancer Cell International
  • Year: 2024

"Longitudinal assessment of quality of life indicators and prognosis in esophageal cancer patients with curative resection" 

  • Authors: Qiu, L.-H. , Liang, S.-H. , Wu, L. , Zhong, J.-D. , Ma, G.-W.
  • Journal: Journal of Thoracic Disease
  • Year: 2024

"Antitumor effects of a Sb-rich polyoxometalate on non-small-cell lung cancer by inducing ferroptosis and apoptosis" 

  • Authors: Lin, J.-W. , Zhou, Y. , Xiao, H.-P. , Li, X.-X. , Li, Z.-X.
  • Journal: Chemical Science
  • Year: 2024